NasdaqGS:TXMD

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

TherapeuticsMD, Inc. operates as a women’s healthcare company in the United States. More Details


Snowflake Analysis

High growth potential and slightly overvalued.


Similar Companies

Share Price & News

How has TherapeuticsMD's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TXMD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: TXMD's weekly volatility has decreased from 18% to 11% over the past year.


Market Performance


7 Day Return

7.5%

TXMD

1.6%

US Pharmaceuticals

0.6%

US Market


1 Year Return

-39.5%

TXMD

2.8%

US Pharmaceuticals

21.0%

US Market

Return vs Industry: TXMD underperformed the US Pharmaceuticals industry which returned 2.8% over the past year.

Return vs Market: TXMD underperformed the US Market which returned 21% over the past year.


Shareholder returns

TXMDIndustryMarket
7 Day7.5%1.6%0.6%
30 Day18.0%4.4%4.2%
90 Day-12.2%8.2%12.4%
1 Year-39.5%-39.5%6.4%2.8%23.7%21.0%
3 Year-76.7%-76.7%23.7%14.0%47.4%37.6%
5 Year-81.0%-81.0%53.2%35.0%131.6%105.9%

Long-Term Price Volatility Vs. Market

How volatile is TherapeuticsMD's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is TherapeuticsMD undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: TXMD ($1.44) is trading below our estimate of fair value ($24.68)

Significantly Below Fair Value: TXMD is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: TXMD is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: TXMD is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TXMD's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TXMD has negative assets, so we can't compare its PB Ratio to the US Pharmaceuticals industry average.


Next Steps

Future Growth

How is TherapeuticsMD forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

60.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TXMD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: TXMD is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: TXMD's is expected to become profitable in the next 3 years.

Revenue vs Market: TXMD's revenue (38.6% per year) is forecast to grow faster than the US market (10.2% per year).

High Growth Revenue: TXMD's revenue (38.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if TXMD's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has TherapeuticsMD performed over the past 5 years?

-21.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TXMD is currently unprofitable.

Growing Profit Margin: TXMD is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: TXMD is unprofitable, and losses have increased over the past 5 years at a rate of 21.4% per year.

Accelerating Growth: Unable to compare TXMD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TXMD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.8%).


Return on Equity

High ROE: TXMD's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is TherapeuticsMD's financial position?


Financial Position Analysis

Short Term Liabilities: TXMD has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: TXMD has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: TXMD has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: TXMD's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TXMD has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if TXMD has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is TherapeuticsMD current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate TXMD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TXMD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TXMD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TXMD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TXMD's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.0yrs

Average management tenure


CEO

Rob Finizio (49 yo)

9.25yrs

Tenure

US$1,222,220

Compensation

Mr. Robert G. Finizio, also known as Rob, is the Co-Founder of TherapeuticsMD, Inc. and has been its Chief Executive Officer since October 4, 2011. Mr. Finizio serves as Director of ZyVersa Therapeutics, I...


CEO Compensation Analysis

Compensation vs Market: Rob's total compensation ($USD1.22M) is about average for companies of similar size in the US market ($USD1.65M).

Compensation vs Earnings: Rob's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Robert Finizio
Co-Founder9.25yrsUS$1.22m6.89%
$ 29.4m
John C. Milligan
President & Secretary9.25yrsUS$1.44m1.88%
$ 8.0m
Mitchell Krassan
Executive VP and Chief Strategy & Performance Officer9.25yrsUS$1.04m0%
$ 0
Michael Donegan
Vice President of Finance7.75yrsUS$572.08k0%
$ 0
Brian Bernick
Co-Founder & Chief Scientific Officerno dataUS$1.21mno data
James D'Arecca
Chief Financial Officer0.58yrno datano data
Jason Spitz
Vice President of Commercial Development & Operationsno datano datano data
Joel Krasnow
Chief Scientific Officer and Head of Regulatory Department7.08yrsno datano data
Adam Miller
Chief Information Officer2.83yrsno datano data
Nichol Ochsner
Vice President of Investor Relations3yrsno datano data
Marlan Walker
General Counsel4.83yrsno datano data
John Knighton
Chief Compliance Officer2.83yrsno datano data

6.0yrs

Average Tenure

50.5yo

Average Age

Experienced Management: TXMD's management team is seasoned and experienced (6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Robert Finizio
Co-Founder9.25yrsUS$1.22m6.89%
$ 29.4m
Gail Naughton
Independent Director0.83yrno datano data
Paul Bisaro
Independent Director0.83yrno data0.017%
$ 72.0k
Angus Russell
Independent Director5.83yrsUS$190.01k0.032%
$ 134.6k
J. Carroll
Independent Director5.83yrsUS$194.51k0.0034%
$ 14.4k
Thomas Thompson
Independent Chairman of the Board8.67yrsUS$277.01k0.24%
$ 1.0m
Cooper Collins
Independent Director8.92yrsUS$202.51k0.047%
$ 201.6k
Jules Musing
Independent Director7.67yrsUS$182.51k0.0017%
$ 7.2k
Karen Ling
Independent Director0.75yrno datano data

5.8yrs

Average Tenure

64yo

Average Age

Experienced Board: TXMD's board of directors are considered experienced (5.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.2%.


Top Shareholders

Company Information

TherapeuticsMD, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: TherapeuticsMD, Inc.
  • Ticker: TXMD
  • Exchange: NasdaqGS
  • Founded: 2008
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$426.600m
  • Shares outstanding: 296.25m
  • Website: https://www.therapeuticsmd.com

Number of Employees


Location

  • TherapeuticsMD, Inc.
  • 951 Yamato Road
  • Suite 220
  • Boca Raton
  • Florida
  • 33431
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TXMDNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDOct 2011
29TDB (Deutsche Boerse AG)YesCommon StockDEEUROct 2011

Biography

TherapeuticsMD, Inc. operates as a women’s healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy c...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/15 00:24
End of Day Share Price2021/01/14 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.